1. Home
  2. NBBK vs SGMT Comparison

NBBK vs SGMT Comparison

Compare NBBK & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NBBK

NB Bancorp Inc.

N/A

Current Price

$22.60

Market Cap

926.5M

Sector

N/A

ML Signal

N/A

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

N/A

Current Price

$9.65

Market Cap

761.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NBBK
SGMT
Founded
1892
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
926.5M
761.6M
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
NBBK
SGMT
Price
$22.60
$9.65
Analyst Decision
Hold
Buy
Analyst Count
2
12
Target Price
$25.00
★ $27.91
AVG Volume (30 Days)
246.2K
★ 1.2M
Earning Date
10-15-2026
11-16-2026
Dividend Yield
★ 1.26%
N/A
EPS Growth
★ 25.23
N/A
EPS
★ 0.90
N/A
Revenue
N/A
★ $2,000,000.00
Revenue This Year
$39.72
N/A
Revenue Next Year
$9.75
N/A
P/E Ratio
$24.57
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.54
$4.50
52 Week High
$23.47
$11.45

Technical Indicators

Market Signals
Indicator
NBBK
SGMT
Relative Strength Index (RSI) 51.20 51.22
Support Level $21.38 $8.54
Resistance Level $22.81 $11.33
Average True Range (ATR) 0.63 0.62
MACD 0.01 0.15
Stochastic Oscillator 63.66 65.25

Price Performance

Historical Comparison
NBBK
SGMT

About NBBK NB Bancorp Inc.

NB Bancorp Inc operates as the holding company of Needham Bank. The group's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, consumer loans, and other related services.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: